Background: The success of antiretroviral therapy requires better virological monitoring. We described the virological profile of patients on combined antiretroviral therapy (cART)
Introduction
The Central African Republic (CAR), landlocked country has undergone a decade of socio-political instability, which has led to a humanitarian crisis and a weakening of the country's health system. The Global Fund to Fight Acquired Immunodeficiency Syndrome (AIDS), Tuberculosis and Malaria and other partners have been worked with local authorities to strengthen the health system and to address the diseases of the century, especially human immunodeficiency virus (HIV/AIDS). In 2010, the prevalence of HIV infection was 4.9% among adults aged 15 -49 years old throughout the country and 7.7% in the capital, Bangui [1] . In 2015, the national center for monitoring internal displacement reported that 368,859 people were in informal camps [2] . In December 2015, in view of the precarity and vulnerability of the population, 18,250 patients with HIV infection received emergency stocks of 3 months of antiretroviral therapy (ART) [3] , which were renewed frequently. With controling and sustaining rapidly, the multiplication of the virus decreased and immunocompetence restored.
Therapeutic success depends on close monitoring from initiation of treatment and over time. Biological and clinical follow-up after 12 months of treatment is essential to evaluate antiretroviral therapy (ART) and to detect HIV resistance [4] [5] . In 2015, the World Health Organization (WHO) recommended that the monitoring of patients on ART should include CD4 cell counts and measurement of HIV plasma viral load; virological failure was defined as a viral load ≥ 1000 copies/mL [6] [7] [8] . In practice, the viral load is estimated from the number of copies of ribonucleic acid (RNA) HIV-1 per milliliter of plasma, determined with commercial molecular technic used to evaluate the effectiveness of ART. 
Patients, Materials and Methods

Sample, RNA Extraction and Real-Time Polymerase Chain Reaction Amplification
A blood sample was taken from all patients for quantification of RNA HIV-1 into a tube with ethylenediamine tetraacetic acid (EDTA), and the plasma was divided into aliquots and stored at −20˚C until doing RNA extraction according to manufacturer's procedures. Biocentric RNA HIV extraction kits (12.08.02 -170,510) and automated methods using NorDiag Arrow extractor (AO637R3) have been used for HIV-RNA extraction. Biocentric RNA HIV amplification kits (TR001-250IC) was used for real-time PCR on Applied Biosystems QuantStudio™5 (A28133). The target region was on the long terminal repeats (LTRs), and the detection limit was 390 copies/mL. The technic is specific for HIV-1 group of M sub-types A-H.
Statistical Analysis
Data were entered onto Excel® sheets and analyzed with Stata software version 14. The data included the sex and age of patients, and viral load, categorized as <300 (virological suppression or undetectable). The viral load was presented as <1000 copies/mL (virological success) and ≥1000 copies /mL (virological failure 
Results
The viral load of 3569 patients was measured during the study period. The mean age was 40 ± 13 years, with a range of 1 -84; most of patients (34.2%) were in the age range to 40 -49 years old (Table 1) . Half of the patients in this study (49.2%) has an undetectable viral load (<300 copies/mL), while the remainder (50.8%) has a detectable viral load ≥ 300 copies/mL. comparison of patients with and without virological failure by age group showed statistically significant differences (Table 3 ).
Discussion
We observed a preponderance of women, with a sex ratio of 0.4, and a median age of 42 years. These results are similar to those of Mouala C et al. [9] , who found a sex ratio of 0.4 and a median age of 32.5 years in a study of factors associated with adherence to treatment among HIV-infected patients in Bangui in 2006. At a detection level of 300 copies/mL of blood plasma, 49.2% of patients had an undetectable viral load (virological suppression). This rate is lower than those found elsewhere, such as 83.3% in Benin [10] , 84% in Morocco [11] and 96% in the west part of the Ile de France (Paris region) [12] . The low rate in the CAR is due to the unstable sociopolitical situation in the country, which has complicated geographical access to treatment and the monitoring of patients. HIV viral load is more available and more accessible in the capital, Bangui, in view of the cost and technical requirements of the test. Samples have taken into tubes containing EDTA, which must be maintained at 4˚C and transferred rapidly to the laboratory four hours after the collect. An alternative to this system would for regional health centres to send dried blood spots (DBS) on filter paper for analysis centrally. The adherence rate measured about 10 years ago in Bangui was 77.5% [9] . Regular measurement in routine practice could increase the rate. The fact that 42.4% of patients are virological failure could result in therapeutic failure for nearly half of all our patients. Virologic failure has often been described and associated with therapeutic failure in the country. In 2012, Pere H et al., according to the 2010 WHO guidelines, observed in RCA, in 386 adult patients on first-line antiretroviral treatment for 24 months, a virological failure in 28.5% (HIV-1 RNA > 3.7 log (10) or 5000 copies/ml). Twenty-four percent of patients in virological failure showed wild-type viruses, likely indicating poor adherence. Even after excluding the M184V mutation, 76% of patients in virological failure displayed viruses harboring at least one major drug resistance mutation to nucleoside reverse transcriptase inhibitors (NRTI), non-NRTI, or protease inhibitors [18] . Moussa S et al., have also studied the emergence of resistance mutations in isolates from CAR patients at failure of d4T-AZT/3TC/ NVP-EFV, the resistance mutations observed are those which are expected on HIV-1 subtype B [19] . These observations point the necessity to monitor patient receiving regimen by plasma HIV-1 RNA load to diagnose situations of therapeutic failure and to operate switch. The same finding was made in children after 18 to 30 months of ARV treatment by Charpentier C et al. in 2012, who found a detectable viral load in 53% of children, 40% of whom were virologically failed (HIV-1 RNA > 3.7 log (10) copies/ml) [20] . Mossoro-Kpinde CD et al. in 2016 had been found in children under 5, on first-and second-line antiretroviral therapy, who have a detectable viral load, a virological failure of 97% [21] . With untreated young children living in the CAR, Charpentier C et al., found that 66% of them showed plasma HIV-1 > 1000 copies/ml and were in virological failure, according to the 2015 WHO guidelines [22] .
Monitoring of patients is important to ensure that the treatment is effective and their health improves, and therapeutic follow-up requires measuring the viral load, which is the main biological method for identifying and confirming The accessibility of HIV viral load is still improvable in the CAR. The limitations of this study relate to other biological parameters of the follow-up that were not sought. Immunological and hematological parameters are also determining factors in the therapeutic evaluation of patients on cART. But given the size of this study and its objective, these parameters were not studied in all patients so not reported. This study, however, updated the virological profile data for a large proportion of patients on antiretroviral therapy and described the trends in HIV viral load by age group and sex. Other studies will deepen the question of the multidisciplinary management of patients under treatment in the CAR.
Conclusion
HIV viral load is more available in Bangui. Virological failure was observed in 42.4% of patients, while 49.2% had undetectable virus. The high rate of virologi-cal failure associated with immunodeficiency could result in therapeutic failure.
It is therefore essential to strengthen monitoring of treatment adherence and improve access to measurement of viral load in Bangui, CAR.
